Skip to main content
An official website of the United States government
Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Principal Investigator
Gary C. Doolittle
Awardee Organization

University Of Kansas Medical Center
United States

Fiscal Year
2025
Activity Code
UG1
Early Stage Investigator Grants (ESI)
Not Applicable
Project End Date

The University of Kansas Cancer Center's- MCA Rural NCORP- extension

The overarching goal for The University of Kansas Cancer Center – Masonic Cancer Alliance Rural NCORP (KUCC-MCA Rural NCORP) is to enhance rural communities access to clinical trials in cancer control, prevention, treatment, care delivery clinical trials, and other human research developed and conducted by NCORP Research Bases. While cancer affects all, rural communities are more at risk than others for poor outcomes.[1] Inaccessibility of clinical trials due to geographic barriers is an often cited reason for not enrolling in studies.[2] KUCC is strongly positioned to continue to enhance clinical trial accrual and participation of rural populations through its leadership of the Masonic Cancer Alliance (MCA) and its cadre of accomplished investigators with extensive experience working with rural communities and practices. The MCA is KUCC’s formal outreach network that has partnered with hospitals, cancer centers, and health care providers across the state of Kansas for close to two decades. The goal of these MCA partnerships is to extend the reach of clinical research across the KUCC catchment area, with a particular focus on rural communities. The MCA includes co-administration and support of our state-wide rural primary care practice-based research network, Kansas Patients and Providers Engaged in Prevention Research (KPPEPR), under the leadership of Dr. K. Allen Greiner, one of KUCC’s leading cancer prevention investigators. KPPEPR is a network engaging primary care providers from across Kansas with a longstanding history of supporting cancer prevention and control research initiatives, 34 who have participated in projects with KUCC in the last five years. The KUCC-MCA Rural NCORP leverages our over 50-year experience as a SWOG-member, nearly 30-year experience providing oncology care via telemedicine, 25-year history of successfully conducting research in rural primary care settings, and 15-year experience opening and running clinical trials within rural health care networks—all supported by KUCC expertise in partnering with rural oncology and primary care practices to accomplish our goals. Specifically, the KUCC-MCA Rural NCORP addresses institutional, provider, clinical trial, and patient barriers to trial accrual, and implemented processes to: 1) Enhance the infrastructure of local cancer centers and primary care offices to support clinical trial accrual; 2) Expand access to NCORP clinical trials across the MCA network; 3) Decrease barriers to clinical trial participation for rural patients across Kansas and western Missouri by providing trial participation opportunities in their home communities; and 4) Leverage KUCC-MCA expertise for addressing rural cancer clinical trial participation with NCORP grantees.

Publications

  • Appleman LJ, Kim SE, Harris WB, Pal SK, Pins MR, Kolesar J, Agarwal N, Parikh RA, Vaena DA, Ryan CW, Hashmi M, Costello BA, Cella D, Dutcher JP, DiPaola RS, Haas NB, Wagner LI, Carducci MA. Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2024 Jun 10;42(17):2061-2070. Epub 2024 Mar 26. PMID: 38531002